{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:50Z","timestamp":1787010170523,"version":"build-2736575974"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,5]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Primary myelofibrosis is a subtype of myeloproliferative neoplasm that leads to bone marrow fibrosis. Historically, the only curative option for primary myelofibrosis was allogeneic hematopoietic stem cell transplant. Ruxolitinib, a Janus kinase inhibitor, is now used for the treatment of primary myelofibrosis and polycythemia vera. It effectively improves symptoms related to splenomegaly and anemia. However, its association with the development of opportunistic infections has been observed in clinical studies and practical application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 64-year-old female with primary myelofibrosis and chronic hepatitis B infection who received ruxolitinib treatment. She was admitted for spiking fever and altered consciousness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis:<\/jats:title>\n                    <jats:p>\n                      Tuberculosis meningitis was suspected but cerebrospinal fluid can\u2019t identify any pathogens. An abdominal computed tomography scan revealed a left psoas abscess and an enlarged spleen. A computed tomography-guided pus drainage procedure was performed, showing a strong positive acid-fast stain and a positive\n                      <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                      polymerase chain reaction result.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>antituberculosis medications were administered. The patient developed a psoas muscle abscess caused by tuberculosis and multiple dermatomes of herpes zoster during antituberculosis treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient was ultimately discharged after 6 weeks of treatment without apparent neurological sequelae.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case underscores the importance of clinicians evaluating latent infections and ensuring full vaccination prior to initiating ruxolitinib-related treatment for primary myelofibrosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000037653","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T14:06:49Z","timestamp":1712326009000},"page":"e37653","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Ruxolitinib associated psoas muscle tuberculosis abscess in a primary myelofibrosis woman: A case report and literature review"],"prefix":"10.1097","volume":"103","author":[{"given":"Chi-Yu","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9258-0692","authenticated-orcid":false,"given":"Tun-Chieh","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Center for Tropical Medicine and Infectious Disease Research and Center for Medical Education and Humanizing Health Professional Education, Kaohsiung Medical University, Kaohsiung, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/1756-0500-5-552","article-title":"Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.","volume":"5","author":"Colomba","year":"2012","journal-title":"BMC Res Notes"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.clml.2019.08.008","article-title":"Mycobacterial infections with ruxolitinib: a retrospective pharmacovigilance review.","volume":"20","author":"Anand","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.14382","article-title":"The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).","volume":"176","author":"Mesa","year":"2017","journal-title":"Br J Haematol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s11899-015-0284-z","article-title":"Immunological consequences of JAK inhibition: friend or foe?","volume":"10","author":"McLornan","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.13373","article-title":"JAK1\/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.","volume":"169","author":"Yajnanarayana","year":"2015","journal-title":"Br J Haematol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41375-020-0890-1","article-title":"Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study.","volume":"34","author":"Crodel","year":"2020","journal-title":"Leukemia"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.3390\/cancers12113132","article-title":"Ruxolitinib-associated infections in polycythemia vera: review of the literature, clinical significance, and recommendations.","volume":"12","author":"Sadjadian","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41375-019-0388-x","article-title":"Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).","volume":"33","author":"Maschmeyer","year":"2019","journal-title":"Leukemia"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"6484","DOI":"10.3748\/wjg.v22.i28.6484","article-title":"Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.","volume":"22","author":"Law","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bjh.16174","article-title":"A journey through infectious risk associated with ruxolitinib.","volume":"187","author":"Sant\u2019Antonio","year":"2019","journal-title":"Br J Haematol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:08:49Z","timestamp":1746317329000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":13,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037653","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]}}}